EFM2 Antibody

What is EFhd2 and why are specific antibodies important for its study?

EFhd2 (EF-hand domain-containing protein D2) is a calcium-binding protein abundantly expressed in brain tissue, immune cells (particularly B cells and monocytes), and various other tissues. Specific antibodies against EFhd2 are critical for studying this protein because:

• EFhd2 belongs to a family that includes the closely related EFhd1, requiring antibodies that can discriminate between these homologous proteins.

• The protein contains distinct functional domains (N-terminal low complexity region, proline-rich region, EF hands, and coiled-coil domain) that may require domain-specific antibodies for comprehensive analysis.

• EFhd2 localizes to multiple subcellular compartments, making specific antibodies essential for accurate localization studies.

• Expression levels vary significantly between cell types, with human monocytes expressing approximately five times more EFhd2 than human B cells, requiring sensitive and specific detection methods .

How are monoclonal EFhd2 antibodies generated?

Monoclonal antibodies against EFhd2 are typically generated through the following methodological approach:

• Immunization: BALB/c mice are immunized with GST-EFhd2 fusion protein (initially 50 μg in complete Freund's adjuvant intraperitoneally), followed by booster immunizations (10 μg GST-EFhd2 with incomplete Freund's adjuvant) at days 25 and 45.

• Titer testing: Antibody titers are evaluated by Western blot analysis using diluted sera (typically 1:200).

• Final boost: The mouse with highest response receives a final immunization (10 μg GST-EFhd2 in PBS intravenously) 5 days before fusion.

• Cell fusion: Spleen cells are fused with myeloma cells following standard hybridoma technology protocols.

• Screening: After 2 weeks, hybridoma clones are screened by ELISA using plates coated with either GST or GST-EFhd2 fusion protein to identify clones recognizing specifically EFhd2 but not the GST tag.

• Validation and subcloning: Positive clones are validated by Western blot and subcloned twice by limiting dilution to ensure monoclonality.

• Purification: Antibodies are purified on Protein G columns according to standard methods .

This rigorous approach ensures the generation of highly specific monoclonal antibodies suitable for research applications.

How can I validate the specificity of anti-EFhd2 antibodies?

Validating antibody specificity is crucial for reliable experimental results. For EFhd2 antibodies, a comprehensive validation approach should include:

• Control cell lines:

  • Use EFhd2-knockout or EFhd2-silenced cell lines (e.g., WEHI231 B cells with shRNA-silenced EFhd2) as negative controls

  • Use cells with reconstituted or overexpressed EFhd2 (e.g., Myc-tagged EFhd2) as positive controls

• Multiple detection methods:

  • Western blot analysis to confirm antibody recognizes a protein of the expected molecular weight (~30 kDa for EFhd2)

  • Immunoprecipitation to verify antibody-antigen interaction

  • Immunocytochemistry/immunofluorescence to assess subcellular localization patterns

  • Flow cytometry to quantify expression levels

• Epitope mapping:

  • Test antibody binding against EFhd2 deletion mutants (ΔLC, ΔPR, ΔEF1, ΔEF2, ΔCC) to identify the recognized epitope

  • Example: Anti-EFhd2 MAbs typically recognize epitopes within the N-terminal low complexity region

• Competition assays:

  • Pre-incubate antibodies with purified antigen (e.g., GST-EFhd2) before staining to demonstrate binding specificity

  • Complete blocking of signal confirms specificity

What are the recommended applications for anti-EFhd2 monoclonal antibodies?

Based on research findings, anti-EFhd2 monoclonal antibodies have been successfully validated for multiple applications:

When designing experiments, researchers should consider that:

• The antibodies recognize an epitope within the N-terminal low complexity region

• They cross-react with both murine and human EFhd2

• They do not cross-react with the homologous EFhd1 protein

• They are particularly effective for distinguishing subcellular localization patterns

How should I design experiments to study EFhd2 subcellular localization?

Studying EFhd2 subcellular localization requires careful experimental design:

• Cell preparation:

  • Include proper controls (EFhd2-negative and EFhd2-positive cells)

  • For adherent cells, grow on coverslips; for suspension cells, cytospin onto slides

  • Fix with 4% paraformaldehyde for structure preservation

• Immunostaining approach:

  • Use anti-EFhd2 monoclonal antibodies at 1:200-1:500 dilution

  • Include co-staining for subcellular markers (e.g., plasma membrane, vesicular structures)

  • To exclude ER localization, co-stain with antibodies against ER chaperones (Calnexin, Calreticulin)

  • Include nuclear staining (e.g., DAPI) to demonstrate the primarily non-nuclear localization

• Confocal microscopy:

  • Use high-resolution confocal microscopy for precise localization

  • Examine multiple Z-sections to distinguish membrane from cytoplasmic staining

  • Assess colocalization with known markers

• Complementary approaches:

  • Confirm findings using subcellular fractionation followed by Western blotting

  • For quantitative assessment, use flow cytometry with permeabilized cells

Research has shown that EFhd2 localizes primarily to the plasma membrane and intracellular vesicular structures, but not significantly to the endoplasmic reticulum or nucleus, which should be evident in properly designed localization experiments .

How can I quantitatively assess EFhd2 expression levels in different cell populations?

For quantitative assessment of EFhd2 expression across different cell populations, flow cytometry offers the most robust approach:

• Sample preparation:

  • Isolate cells of interest (e.g., PBMCs for human samples)

  • Fix with 2-4% paraformaldehyde

  • Permeabilize with 0.1-0.5% Triton X-100 or saponin-based permeabilization buffer

• Staining protocol:

  • Block with 2-5% serum (matching secondary antibody species)

  • Stain with anti-EFhd2 antibody (1-5 μg/10^6 cells)

  • For multicolor analysis, include surface markers for population identification

  • Include proper isotype control (IgG1κ for most anti-EFhd2 MAbs)

• Calibration and controls:

  • Use cells expressing GFP alone as negative control

  • Use cells overexpressing EFhd2 for positive control and calibration

  • Generate a standard curve with varying EFhd2 expression levels

• Analysis considerations:

  • Measure mean fluorescence intensity (MFI) for quantitative comparisons

  • Normalize to control populations for consistent results

  • For absolute quantification, consider using calibration beads

Research has demonstrated that this approach allows linear quantification of EFhd2 expression across a 2-log scale. Importantly, human monocytes express approximately five times more EFhd2 than human B cells, providing a useful internal reference for quantification .

What are common pitfalls in EFhd2 immunodetection and how can they be addressed?

Several technical challenges may arise when working with EFhd2 antibodies:

• Cross-reactivity concerns:

  • Problem: Potential cross-reactivity with EFhd1 due to sequence homology

  • Solution: Use validated monoclonal antibodies specifically tested against both proteins

  • Validation approach: Test antibodies against cell lines expressing only EFhd1 or EFhd2

• Epitope accessibility issues:

  • Problem: N-terminal epitopes recognized by most anti-EFhd2 MAbs may be masked in certain contexts

  • Solution: Use multiple antibodies recognizing different epitopes when possible

  • Alternative: Adjust fixation and permeabilization protocols to preserve epitope structure

• Expression level detection limits:

  • Problem: Endogenous EFhd2 levels may be below detection threshold in some cells

  • Solution: Optimize signal amplification (e.g., TSA for IHC/ICC) or use more sensitive detection methods

  • Enhancement: Consider enrichment by immunoprecipitation before Western blotting

• Background in immunostaining:

  • Problem: Non-specific staining in certain tissues or cells

  • Solution: Increase blocking stringency (use 5% BSA with 0.1% Triton X-100)

  • Control: Pre-incubate antibody with GST-EFhd2 fusion protein to confirm specificity

How do I optimize Western blotting protocols for EFhd2 detection?

For optimal Western blot detection of EFhd2, consider the following methodology refinements:

• Sample preparation:

  • Lyse cells in RIPA buffer containing protease inhibitors and phosphatase inhibitors

  • For brain tissue samples, use special consideration for protein extraction efficiency

  • Include 1-2 mM calcium chelators (EDTA/EGTA) to prevent calcium-dependent protein interactions

• Gel electrophoresis parameters:

  • Use 12-15% polyacrylamide gels for optimal resolution around 30 kDa

  • Load 10-30 μg of total protein per lane depending on EFhd2 abundance in sample

  • Include phosphorylation-dependent mobility shift controls if studying modifications

• Transfer optimization:

  • Use PVDF membranes (0.45 μm) for standard applications

  • Consider wet transfer methods for consistent results

  • Transfer at 100V for 1 hour or 30V overnight at 4°C

• Immunodetection protocol:

  • Block with 5% non-fat dry milk in TBS-T (standard) or 3% BSA (for phospho-specific detection)

  • Incubate with primary anti-EFhd2 antibody (1:1000-1:5000) overnight at 4°C

  • Use appropriate HRP-conjugated secondary antibody (typically anti-mouse IgG)

  • For low expression samples, consider enhanced chemiluminescence detection systems

• Controls and validation:

  • Include positive control (brain lysate shows abundant EFhd2 expression)

  • Include negative control (EFhd2-knockout or silenced cells)

  • For antibody validation, use competition with purified antigen

How can I effectively use anti-EFhd2 antibodies for co-immunoprecipitation studies?

For successful co-immunoprecipitation (co-IP) studies investigating EFhd2 protein interactions:

• Lysis buffer optimization:

  • Use mild non-denaturing buffers (e.g., 1% NP-40 or 0.5% Triton X-100 in PBS)

  • Include protease and phosphatase inhibitors

  • Consider the impact of calcium: use buffers with either 2 mM CaCl₂ or 2 mM EGTA to examine calcium-dependent interactions

• Pre-clearing strategy:

  • Pre-clear lysates with Protein G beads to reduce non-specific binding

  • Save a sample of pre-cleared lysate as input control

• Immunoprecipitation approach:

  • For direct IP: Incubate 1-5 μg antibody with 500-1000 μg protein lysate for 2-4 hours at 4°C

  • For pre-coupled approach: Conjugate antibody to Protein G beads before adding to lysate

  • Include appropriate controls (isotype-matched control antibody, IP from EFhd2-negative cells)

• Washing conditions:

  • Use at least 4-5 washes with lysis buffer

  • Consider increasing stringency in later washes to reduce background

  • For weak interactions, maintain consistent cold temperature throughout procedure

• Elution and detection:

  • Elute with SDS sample buffer at 95°C for 5 minutes

  • Analyze by Western blot, probing for both EFhd2 and potential interacting partners

  • Consider mass spectrometry for unbiased identification of novel interacting proteins

How can anti-EFhd2 antibodies be used to study calcium-dependent conformational changes?

EFhd2 contains two EF-hand calcium-binding domains that mediate calcium-dependent conformational changes, which can be studied using:

• Differential antibody reactivity approach:

  • Compare antibody binding in the presence/absence of calcium

  • Prepare parallel lysates with either calcium-containing or calcium-chelating buffers

  • Test whether epitope accessibility changes under different calcium conditions

  • Western blotting may reveal calcium-dependent mobility shifts

• Co-immunoprecipitation under varying calcium conditions:

  • Perform parallel IPs in buffers containing either 2 mM CaCl₂ or 2 mM EGTA

  • Analyze interaction partners that associate with EFhd2 in a calcium-dependent manner

  • Quantify differences in binding efficiency under different calcium conditions

• Conformational epitope exposure:

  • Test multiple antibodies recognizing different epitopes

  • Determine if calcium affects accessibility of specific domains

  • Map calcium-sensitive regions through domain deletion mutants

• Live cell imaging:

  • Create calcium sensor constructs by fusing EFhd2 with fluorescent proteins

  • Use antibody-based detection in fixed cells after calcium ionophore treatment

  • Compare subcellular localization under different calcium conditions

What approaches can be used to study EFhd2 in brain tissue and neurodegenerative diseases?

For studying EFhd2 in brain tissue and its potential role in neurodegenerative diseases:

• Immunohistochemistry optimization:

  • Use 4% paraformaldehyde-fixed, paraffin-embedded sections (5-10 μm thickness)

  • Perform antigen retrieval (citrate buffer, pH 6.0, 95°C for 20 minutes)

  • Use anti-EFhd2 antibodies at 1:100-1:500 dilution

  • Employ DAB (3,3'-diaminobenzidine) visualization for brightfield microscopy

  • For fluorescence, use appropriate fluorophore-conjugated secondary antibodies

• Co-localization studies:

  • Perform double immunofluorescence with markers for:

    • Neurons (NeuN, MAP2)

    • Glial cells (GFAP for astrocytes, Iba1 for microglia)

    • Synaptic markers (synaptophysin, PSD-95)

    • Pathological proteins (tau, β-amyloid, α-synuclein)

  • Analyze using confocal microscopy and colocalization quantification

• Expression analysis in disease models:

  • Compare EFhd2 levels between normal and diseased tissue

  • Use Western blotting for quantitative comparison

  • Examine region-specific differences in expression

  • Correlate with disease progression markers

• Cellular fractionation:

  • Separate cytosolic, membrane, and insoluble protein fractions

  • Analyze EFhd2 distribution between fractions in normal vs. diseased tissue

  • Determine if EFhd2 shifts to insoluble fractions in neurodegenerative conditions

Research has confirmed EFhd2 protein expression in murine brain using both monoclonal and polyclonal antibodies, with specific localization patterns that may be altered in neurodegenerative diseases .

How can I analyze post-translational modifications of EFhd2 using antibody-based methods?

Analyzing post-translational modifications (PTMs) of EFhd2 requires specialized approaches:

• Phosphorylation analysis:

  • Treat cells with phosphatase inhibitors during lysis

  • Use Phos-tag™ gels to enhance mobility shifts of phosphorylated proteins

  • Perform immunoprecipitation with anti-EFhd2 antibodies followed by Western blotting with phospho-specific antibodies

  • For sites without available phospho-specific antibodies, use mass spectrometry after IP

• Calcium-binding assessment:

  • Perform native gel electrophoresis to preserve calcium-dependent conformations

  • Compare migration in the presence of calcium vs. EGTA

  • Use proximity ligation assays to detect calcium-dependent interactions in situ

• Ubiquitination/SUMOylation detection:

  • Add deubiquitinase inhibitors to lysis buffer

  • Perform IP under denaturing conditions to disrupt non-covalent interactions

  • Western blot with anti-ubiquitin or anti-SUMO antibodies

  • Verify with reciprocal IP (anti-ubiquitin IP followed by EFhd2 detection)

• Protocol for detecting multiple PTMs:

  • First IP: Use anti-EFhd2

  • Divide precipitate into multiple samples

  • Analyze each sample for different PTMs (phosphorylation, ubiquitination, etc.)

  • Compare modifications across experimental conditions

• Subcellular localization of modified EFhd2:

  • Perform fractionation (cytosolic, membrane, nuclear)

  • Analyze each fraction for differently modified forms

  • Correlate modifications with subcellular distribution

How do anti-EFhd2 antibodies perform across different species and what are the cross-reactivity considerations?

Research on anti-EFhd2 antibodies reveals important cross-species applicability:

• Species reactivity profile:

  • The generated monoclonal anti-EFhd2 antibodies recognize both murine and human EFhd2

  • This cross-reactivity enables comparative studies between mouse models and human samples

  • Specifically, antibodies A4.15.28, A4.15.48, A4.18.18, and E7.20.23 all demonstrate this dual-species reactivity

• Cross-reactivity considerations:

  • EFhd2 antibodies do not cross-react with the homologous EFhd1 protein

  • This specificity is critical since both proteins share similar domain organization

  • The antibodies specifically recognize the N-terminal low complexity region of EFhd2, which likely differs sufficiently from EFhd1

• Validation across species:

  • Human PBMC testing shows specific staining in both monocytes and B cells

  • Flow cytometry reveals higher expression in human monocytes (approximately 5× higher than B cells)

  • Western blot analysis confirms similar molecular weight detection across species

What methodological approaches can compare EFhd2 expression between tissue types and disease states?

For comparative studies of EFhd2 across tissues and disease states:

• Quantitative Western blot protocol:

  • Prepare multiple tissue lysates using identical lysis conditions

  • Include recombinant EFhd2 standards at known concentrations

  • Load equal protein amounts (20-30 μg) per lane

  • Use housekeeping proteins (β-actin, GAPDH) for normalization

  • Employ fluorescent secondary antibodies for wider linear detection range

  • Analyze using densitometry software with standard curve calibration

• Immunohistochemistry comparison:

  • Process all tissues simultaneously with identical protocols

  • Use tissue microarrays for multi-sample comparisons

  • Employ automated staining platforms for consistency

  • Quantify staining intensity using digital image analysis

  • Score both intensity and percentage of positive cells

• Flow cytometry for cell-type specific analysis:

  • Isolate cells from different tissues or disease states

  • Use consistent staining protocol across all samples

  • Include lineage markers to identify specific cell populations

  • Quantify mean fluorescence intensity (MFI) for direct comparisons

  • Use calibration beads to convert MFI to molecules of equivalent soluble fluorochrome

• Multi-omics integration:

  • Correlate protein expression data with transcriptomic data

  • Consider phosphorylation or other PTM states across conditions

  • Integrate with interaction partner analysis for functional context

How should I design experiments to study functional effects of EFhd2 antibodies in cellular systems?

For studying functional effects of EFhd2 antibodies in cellular systems:

• Antibody-mediated functional modulation:

  • Test whether antibody binding activates or inhibits EFhd2 function

  • Assess calcium-binding capacity in the presence of antibodies

  • Determine if antibodies affect protein-protein interactions

• Internalization experiments:

  • Label antibodies with pH-sensitive fluorophores

  • Track internalization kinetics in live cells

  • Determine subcellular localization after internalization

  • Assess colocalization with endosomal/lysosomal markers

• Designing cellular assays:

  • Measure calcium flux in cells treated with EFhd2 antibodies

  • Assess cytoskeletal rearrangements (EFhd2 interacts with actin)

  • Evaluate effects on cell migration or morphology

  • Study impact on receptor internalization or recycling

• Functional readouts in immune cells:

  • For B cells: measure BCR signaling, calcium flux, proliferation

  • For monocytes: assess cytokine production, phagocytosis, migration

  • Complement these studies with genetic approaches (EFhd2 knockdown/knockout)

  • Compare antibody-mediated effects with genetic manipulation results